The effect of Ingenol-B on the suppressive capacity of elite suppressor HIV-specific CD8+ T cells

PLoS ONE

Volumn 12, Issue 5, 2017, Pages

  Kwaa, Abena K ^a   Goldsborough, Kennedy ^a,c   Walker Sperling, Victoria E ^a,d   Pianowski, Luiz F ^b   Gama, Lucio ^a   Blankson, Joel N ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Kyolab   (Brazil)

^c HAMPTON UNIVERSITY   (United States)

^d FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; INGENOL; INGENOL B; UNCLASSIFIED DRUG; (+)-JQ1 COMPOUND; AZEPINE DERIVATIVE; DITERPENE; TRIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IN VITRO STUDY; MALE; VIRUS INHIBITION; VIRUS LATENCY; VIRUS REPLICATION; CELL DEATH; DOSE RESPONSE; DRUG EFFECTS; FLOW CYTOMETRY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; LYMPHOCYTE ACTIVATION;

AZEPINES; CD8-POSITIVE T-LYMPHOCYTES; CELL DEATH; DITERPENES; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; TRIAZOLES;

EID: 85018725997     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0174516     Document Type: Article

References (32)

1. SilicianoJD, SilicianoRF. HIV-1 eradication strategies: design and assessment. CurrOpin HIV AIDS. 2013 Jul; 8(4):318-25. https://doi.org/10.1097/COH.0b013e328361eaca PMID: 23698561
2. Archin NM, Margolis DM. Emerging strategies todeplete the HIV reservoir. CurrOpin Infect Dis. 2014 Feb; 27(1):29-35
3. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, et al.Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012 Jul 25; 487(7408):482-5. https://doi.org/10.1038/nature11286 PMID: 22837004
4. Elliott JH, Wightman F, Solomon A, Ghneim K, Ahlers J, Cameron MJ, et al.Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoSPathog. 2014 Nov13; 10(10):e1004473
5. Rasmussen TA, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C, Solomon A, et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV. 2014Oct; 1(1):e13-21
6. Sogaard OS, Graversen ME, Leth S, Olesen R, Brinkmann CR, Nissen SK, et al. The DepsipeptideRomidepsin Reverses HIV-1 Latency In Vivo. PLoSPathog. 2015 Sep 17; 11(9):e1005142
7. Pace M, Williams J, Kurioka A, Gerry AB, Jakobsen B, Klenerman P,et al. Histone Deacetylase Inhibitors Enhance CD4 T Cell Susceptibility toNK Cell Killing but Reduce NK Cell Function. PLoSPathog. 2016 Aug 16; 12(8):e1005782
8. GarridoC, Spivak AM, Soriano-Sarabia N, Checkley MA, Barker E, Karn J, et al. HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function. Front Immunol in press 2016
9. Akimova T, Beier UH, LiuY, Wang L, Hancock WW. Histone/protein deacetylases and T-cell immune responses. Blood. 2012 Mar 15; 119(11):2443-51. https://doi.org/10.1182/blood-2011-10-292003 PMID: 22246031
10. Jones RB, OConnor R, Mueller S, Foley M, SzetoGL, Karel D,et al. Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes. PLoSPathog. 2014 Aug 14; 10 (8):e1004287
11. Walker-Sperling VE, Pohlmeyer CW, Tarwater PM, Blankson JN. The Effect of Latency Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication. EBioMedicine. 2016 Jun; 8:217-29. https://doi.org/10.1016/j.ebiom.2016.04. 019 PMID: 27428432
12. Clutton G, XuY, Baldoni PL, Mollan KR, Kirchherr J, Newhard W, et al. The differential short-and longterm effects of HIV-1 latency-reversing agents on T cell function. Sci Rep. 2016 Aug 2; 6:30749. https:// doi.org/10.1038/srep30749 PMID: 27480951
13. Lucera MB, Tilton CA, MaoH, Dobrowolski C, Tabler CO, Haqqani AA, et al. The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells toHIV by increasing the kinetics and efficiency of postentry viral events. J Virol. 2014 Sep; 88(18):10803-12 https://doi.org/ 10.1128/JVI.00320-14 PMID: 25008921
14. Laird GM, Bullen CK, Rosenbloom DI, Martin AR, Hill AL, Durand CM, et al. Ex vivoanalysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest. 2015 May; 125(5):1901-12 https:// doi.org/10.1172/JCI80142 PMID: 25822022
15. Darcis G, Kula A, Bouchat S, Fujinaga K, Corazza F, Ait-Ammar A, et al. An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitroand Ex VivoHIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 toPotently Reactivate Viral Gene Expression. PLoSPathog. 2015 Jul 30; 11(7):e1005063
16. Shang H, Ding J, YuS, WuT, Zhang Q, Liang F. Progress and challenges in the use of latent HIV-1 reactivating agents. ActaPharmacologicaSinica. 2015; 36(8):908-916
17. PandeloJose D, Bartholomeeusen K, da Cunha RD, AbreuCM, Glinski J, da Costa TB, et al. Reactivation of latent HIV-1 by new semi-synthetic ingenol esters. Virology. 2014; 0:328-339
18. Fujiwara M, OkamotoM, Ijichi K, Tokuhisa K, Hanasaki Y, Katsuura K, et al. Upregulation of HIV-1 replication in chronically infected cells by ingenol derivatives. Arch. Virol. 1998; 143: 2003. PMID: 9856087
19. AbreuCM, Price SL, Shirk EN, Cunha RD, Pianowski LF,Clements JE, et al. Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novoinfection and activation of viral LTR. PLoS One. 2014 May 14; 9(5):e97257. https://doi.org/10.1371/journal.pone.0097257 PMID: 24827152
20. Spivak AM, Bosque A, Balch AH, Smyth D, Martins L, Planelles V. Ex VivoBioactivity and HIV-1 Latency Reversal by IngenolDibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients. Antimicrob Agents Chemother. 2015 Oct; 59(10):5984-91. https://doi.org/10.1128/AAC. 01077-15 PMID: 26169416
21. Jiang G, Mendes EA, Kaiser P, Wong DP, Tang Y, Cai I, et al Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation. PLoSPathog. 2015 Jul 30; 11(7):e1005066
22. Gama L, AbreuCM, Shirk EN, Price SL, Li M, Laird GM, et al. Reactivation of SIV reservoirs in the brain of virally suppressed macaques. AIDS. 2016 Sep 20
23. OConnell KA, Bailey JR, Blankson JN. Elucidating the elite: mechanisms of control in HIV-1 infection. Trends Pharmacol Sci. 2009 Dec; 30(12):631-7. https://doi.org/10.1016/j.tips.2009.09.005 PMID: 19837464
24. Migueles SA, LaboricoAC, Shupert WL, Sabbaghian MS, Rabin R, Hallahan CW,et al. HIV-specific CD8 + T cell proliferation is coupled toperforin expression and is maintained in nonprogressors. Nat. Immunol. 2002; 3:1061-1068 https://doi.org/10.1038/ni845 PMID: 12368910
25. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8 + T cells. Blood. 2006; 107:4781-4789 https://doi. org/10.1182/blood-2005-12-4818 PMID: 16467198
26. Saez-Cirion A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, Boufassa F, et al., AgenceNationale de Recherches sur le Sida EP36 HIV Controllers Study Group HIV controllers exhibit potent CD8 T cell capacity tosuppress HIV infection ex vivoand peculiar cytotoxic T lymphocyte activation phenotype. Proc. Natl. Acad. Sci. U. S. A. 2007; 104:6776-6781 https://doi.org/10.1073/pnas.0611244104 PMID: 17428922
27. Migueles SA, Osborne CM, Royce C, Compton AA, Joshi RP, Weeks KA, et al. Lytic granule loading of CD8 + T cells is required for HIV-infected cell elimination associated with immune control. Immunity. 2008; 29:1009-1021. https://doi.org/10.1016/j.immuni.2008.10.010 PMID: 19062316
28. Hersperger AR, Pereyra F, Nason M, Demers K, Sheth P, Shin LY, et al. Perforin expression directly ex vivoby HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoSPathog. 2010; 6
29. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8 + T cells. Blood. 2006; 107:4781-4789 https://doi. org/10.1182/blood-2005-12-4818 PMID: 16467198
30. BuckheitRW 3rd, SilicianoRF, Blankson JN. Primary CD8+ T cells from elite suppressors effectively eliminate non-productively HIV-1 infected resting and activated CD4+ T cells. Retrovirology. 2013 Jul 1; 10:68. https://doi.org/10.1186/1742-4690-10-68 PMID: 23816179
31. Smith BD, Jones RJ, ChoE, Kowalski J, Karp JE, Gore SD, et al.Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF. Leukemia research. 2011; 35(1):87-94. https://doi.org/10.1016/j.leukres.2010.06.001 PMID: 20598742
32. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang HC, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity. 2012 Mar 23; 36(3):491-501 https://doi.org/10.1016/j.immuni.2012.01.014 PMID: 22406268